These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8259772)

  • 1. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
    Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
    Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
    Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
    Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
    J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
    N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Hsieh SC; Peterson J; Zheng C; Kelly SE; Shea B; Tugwell P
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD003376. PubMed ID: 38591743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
    Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
    Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
    Iwamoto J; Takeda T; Ichimura S
    J Orthop Sci; 2001; 6(6):487-92. PubMed ID: 11793169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
    Storm T; Steiniche T; Thamsborg G; Melsen F
    J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
    Hasling C; Charles P; Jensen FT; Mosekilde L
    Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study.
    Lyritis GP; Tsakalakos N; Paspati I; Skarantavos G; Galanos A; Androulakis C
    Clin Rheumatol; 1997 Jun; 16(4):354-60. PubMed ID: 9259248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD003376. PubMed ID: 18254018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
    N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.